Advertisement
Research Article| Volume 352, ISSUE 1-2, P68-73, May 15, 2015

Download started.

Ok

Serum levels of procalcitonin and high sensitivity C-reactive protein are associated with long-term mortality in acute ischemic stroke

Published:March 26, 2015DOI:https://doi.org/10.1016/j.jns.2015.03.032

      Highlights

      • PCT and Hs-CRP were associated with ischemic stroke severity.
      • Non-survivors had significantly increased PCT and Hs-CRP levels on admission.
      • Multivariate COX regression analysis showed that PCT and Hs-CRP were independent mortality predictors.
      • The prognostic accuracy of PCT was higher compared to Hs-CRP, NIHSS score and other markers.

      Abstract

      Objective

      The aim of this study is to assess the prognostic value of systemic inflammation, as measured by the inflammatory biomarkers PCT and Hs-CRP, to predict the long-term mortality in ischemic stroke patients.

      Methods

      We prospectively studied 374 patients with ischemic stroke who were admitted within 24 h after the onset of symptoms. Serum levels of PCT, Hs-CRP and NIH stroke scale (NIHSS) were measured at the time of admission. Clinical follow-up was performed at 1 year. The prognostic value of PCT to predict the mortality within one year was compared with Hs-CRP, NIHSS and with other known outcome predictors.

      Results

      In the 64 non-survival patients, serum PCT levels were significantly (P < 0.0001) higher compared with those in survival patients. Multivariate COX regression analysis showed that log-transformed PCT and Hs-CRP were independent mortality predictors with adjusted hazard ratio of 4.24 (95% confidence interval [CI], 2.42–6.30) and 15.37 (95% confidence interval [CI], 3.25–41.08). The area under the receiver operating characteristic curve of PCT and Hs-CRP were 0.89 (95% CI, 0.85–0.93) and 0.68 (95% CI, 0.59–0.77) for mortality, respectively.

      Conclusion

      Serum levels of PCT and HS-CRP at admission were independent predictor of long-term mortality after ischemic stroke in a Chinese sample.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of the Neurological Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Bonita R.
        • Mendis S.
        • Truelsen T.
        • Bogousslavsky J.
        • Toole J.
        • Yatsu F.
        The global stroke initiative.
        Lancet Neurol. 2004; 3: 391-393
        • Slot K.B.
        • Berge E.
        • Dorman P.
        • Lewis S.
        • Dennis M.
        • Sandercock P.
        Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies.
        BMJ. 2008; 336: 376-379
        • Qi A.
        • Li Y.
        • Liu Q.
        • et al.
        Thioredoxin is a novel diagnostic and prognostic marker in patients with ischemic stroke.
        Free Radic Biol Med. 2015; 80: 129-135
        • Tu W.J.
        • Zhao S.J.
        • Liu T.G.
        • et al.
        Combination of high-sensitivity C-reactive protein and homocysteine predicts the short-term outcomes of Chinese patients with acute ischemic stroke.
        Neurol Res. 2013; 35: 912-921
        • Vibo R.
        • Kõrv J.
        • Roose M.
        • Kampus P.
        • Muda P.
        • Zilmer K.
        • Zilmer M.
        Free Radic Res. Acute phase proteins and oxidised low-density lipoprotein in association with ischemic stroke subtype, severity and outcome.
        Free Radic Res. 2007; 41: 282-287
        • Yoldas T.
        • Gonen M.
        • Godekmerdan A.
        • Ilhan F.
        • Bayram E.
        The serum high-sensitive C reactive protein and homocysteine levels to evaluate the prognosis of acute ischemic stroke.
        Mediators Inflamm. 2007; 2007: 15929
        • Maruna P.
        • Nedelnikova K.
        • Gurlich R.
        Physiology and genetics of procalcitonin.
        Physiol Res. 2000; 49: S57-S62
        • Mimoz O.
        • Edouard A.R.
        • Samii K.
        • et al.
        Procalcitonin and C-reactive protein during the early posttraumatic systemic inflammatory response syndrome.
        Intensive Care Med. 1998; 24: 185-188
        • Hatano S.
        Experience from a multicentre stroke register: a preliminary report.
        Bull World Health Organ. 1976; 54: 541-553
        • Adams Jr., H.P.
        • Bendixen B.H.
        • Kappelle L.J.
        • Biller J.
        • Love B.B.
        • Gordon D.L.
        • Marsh III, E.E.
        Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.
        Stroke. 1993; 24: 35-41
        • Bamford J.
        • Sandercock P.
        • Dennis M.
        • et al.
        Classification and natural history of clinically identifiable subtypes of cerebral infarction.
        Lancet. 1991; 337: 1521-1526
        • Brott T.
        • Marler J.R.
        • Olinger C.P.
        • Adams Jr., H.P.
        • Tomsick T.
        • Barsan W.G.
        • et al.
        Measurements of acute cerebral infarction: lesion size by computed tomography.
        Stroke. 1989; 20: 871-875
        • Sims J.R.
        • Gharai L.R.
        • Schaefer P.W.
        • Vangel M.
        • Rosenthal E.S.
        ABC/2 for rapid clinical estimate of infarct, perfusion, and mismatch volumes.
        Neurology. 2009; 72: 2104-2110
        • Simon L.
        • Gauvin F.
        • Amre D.K.
        • et al.
        Serum procalcitonin and C-reactive protein levels as markers of bacterial infection: a systematic review and meta-analysis.
        Clin Infect Dis. 2004; 39: 206-217
        • Sakr Y.
        • Sponholz C.
        • Tuche F.
        • Brunkhorst F.
        • Reinhart K.
        The role of procalcitonin in febrile neutropenic patients: review of the literature.
        Infection. 2008; 36: 396-407
        • McGrane S.
        • Girard T.D.
        • Thompson J.L.
        • et al.
        Procalcitonin and C-reactive protein levels at admission as predictors of duration of acute brain dysfunction in critically ill patients.
        Crit Care. 2011; 15: R78
        • Schiopu A.
        • Hedblad B.
        • Engström G.
        • et al.
        Plasma procalcitonin and the risk of cardiovascular events and death: a prospective population‐based study.
        J Intern Med. 2012; 272: 484-491
        • Katan M.
        • Moon Y.P.
        • DeRosa J.
        • et al.
        Procalcitonin, copeptin and midregional pro-atrial natriuretic peptide as markers of ischemic stroke risk: the Northern Manhattan Study.
        Stroke. 2014; 45: A54-A54
        • Danesh J.
        • Collins R.
        • Appleby P.
        • Peto R.
        Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies.
        JAMA. 1998; 279: 1477-1482
        • Huang Y.
        • Jing J.
        • Zhao X.Q.
        • Wang C.X.
        • Wang Y.L.
        • Liu G.F.
        • Wang C.J.
        • Liu L.P.
        • Yang X.M.
        • Jiao Y.
        • Jiao Y.
        • Wang L.S.
        • Wang Y.J.
        • Gu W.K.
        High-sensitivity C-reactive protein is a strong risk factor for death after acute ischemic stroke among Chinese.
        CNS Neurosci Ther. 2012; 18: 261-266
        • Elkind M.S.
        • Tai W.
        • Coates K.
        • Paik M.C.
        • Sacco R.L.
        High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke.
        Arch Intern Med. 2006; 166: 2073-2080
        • Schuetz P.
        • Suter-Widmer I.
        • Chaudri A.
        • Christ-Crain M.
        • Zimmerli W.
        • et al.
        Prognostic value of procalcitonin in community-acquired pneumonia.
        Eur Respir J. 2011; 37: 384-392
        • Luyt C.E.
        • Guérin V.
        • Combes A.
        • et al.
        Procalcitonin kinetics as a prognostic marker of ventilator-associated pneumonia.
        Am J Respir Crit Care Med. 2005; 171: 48-53
        • Fluri F.
        • Morgenthaler N.G.
        • Mueller B.
        • Christ-Crain M.
        • Katan M.
        Copeptin, procalcitonin and routine inflammatory markers—predictors of infection after stroke.
        PLoS One. 2012; 7: e48309
        • Sacco R.L.
        • Boden-Albala B.
        • Chen X.
        • Lin I.F.
        • Kargman D.E.
        • Paik M.C.
        Relationship of 6-month functional outcome and stroke severity: implications for acute stroke trials from the Northern Manhattan Stroke Study [abstract].
        Neurology. 1998; 50: A327
        • Adams Jr., H.P.
        • Davis P.H.
        • Leira E.C.
        • et al.
        Baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Org 10172 in Acute Stroke Treatment (TOAST).
        Neurology. 1999; 53: 126-131
        • Castelli G.P.
        • Pognani C.
        • Meisner M.
        • et al.
        Procalcitonin and C-reactive protein during systemic inflammatory response syndrome, sepsis and organ dysfunction.
        Crit Care. 2004; 8: R234
        • Wheeler A.P.
        • Bernard G.R.
        Treating patients with severe sepsis.
        N Engl J Med. 1999; 340: 207-214